Primary Medications Available ( per ro.co ): Wegovy (semaglutide 2.4 mg) - FDA-approved for chronic weight management Zepbound (tirzepatide) - FDA-approved for chronic weight management, available in both pen and vial formulations Ozempic (semaglutide 2.0 mg) - FDA-approved for type 2 diabetes, may be prescribed off-label for weight loss Clinical Trial Results for Weight Loss : According to FDA-reviewed clinical trials, Wegovy (semaglutide 2.4 mg) produced average weight loss of 15% of body weight over 68 weeks when combined with lifestyle modifications According to published SURMOUNT trial data, Zepbound (tirzepatide 15 mg) produced average weight loss of 20% of body weight over 72 weeks when combined with lifestyle modifications Both results significantly exceeded placebo groups (2.4-3.1% weight loss) Membership Structure ( per ro.co , November 2025): First Month : $45 introductory rate Ongoing Months : $145/month recurring subscription Medication Costs : Separate from membership, varies by selection and insurance coverage What's Included in Membership ( according to ro.co ): Up to 24 provider consultations annually Unlimited secure messaging with healthcare coach Insurance concierge service for medication coverage assistance Metabolic lab testing when ordered by provider (Quest included for most members) Digital weight tracking and dose logging tools Evidence-based educational curriculum Side effect management support Cash-Pay Medication Pricing ( as listed on ro.co, November 2025, subject to verification): Zepbound vials via LillyDirect: $349-$499/month Wegovy pens via NovoCare: $499/month Zepbound pens: Approximately $1,050/month Ozempic: Pricing varies by pharmacy Insurance Coverage Path : Dedicated concierge team handles prior authorization paperwork Process typically takes 2-3 weeks for coverage determination If approved, members pay only insurance plan copay amounts Appeals assistance available if initially denied Member Survey Data ( per ro.co ): 87% of 1,243 surveyed members reported life-changing results 93% agreed Ro was easier to incorporate than previous weight loss attempts 97% reported reduced "food noise" (reduced food preoccupation) Note: Survey participants were compensated for testimonials Eligibility Requirements : Age 18+ (some services 21+) BMI 30 or BMI 27 with weight-related conditions No personal/family history of medullary thyroid carcinoma (MTC) No Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Not pregnant or breastfeeding Resident of state where Ro operates State Availability : Available in most U.S
If more than 4 days have passed, skip the missed dose and take the next dose on your regular day
National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis
The mechanism of action is documented across the largest body of evidence
Health Secretary Wes Streeting said: "This is a victory in the fight against the shameless criminals who are putting lives at risk
According to Douglas Ewing, MD, FACS, DABOM, a board-certified bariatric surgeon and medical director of the Center for Weight Loss and Metabolic Health at Hackensack University Medical Center, and associate professor of surgery at Hackensack Meridian School of Medicine in New Jersey, the FDAs 503B bulks list identifies bulk drug substances that outsourcing facilities can use to compound medications
